Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension

NCT03901352 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT03901352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03901352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 12, 2019
Completion date
December 28, 2020
Enrollment
300 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

central neuropathic pain